AllianceBernstein
CAI

AllianceBernstein’s Caris Life Sciences CAI Stock Holding History

AllianceBernstein’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.45M Buy
81,021
+23,945
+42% +$429K ﹤0.01% 2208
2026
Q1 		$1.54M Buy
57,076
+36,689
+180% +$802K ﹤0.01% 2137
2025
Q4 		$550K Sell
20,387
-1,181,598
-98% -$33.3M ﹤0.01% 2615
2025
Q3 		$36.4M Buy
1,201,985
+264,434
+28% +$8.43M 0.01% 707
2025
Q2 		$25.1M Buy
+937,551
New +$25.3M 0.01% 820

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AllianceBernstein's CAI Position: Q2 2026 in Review

AllianceBernstein increased its Caris Life Sciences (CAI) stake by 42% in Q2 2026, buying an estimated $429K and bringing the position to 81,021 shares worth $1.45M. The position accounts for ﹤0.01% of the portfolio, ranked #2208.

AllianceBernstein first reported a position in CAI in Q2 2025 and has held it in 5 quarters since. The position peaked at $36.4M in Q3 2025. 246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • AllianceBernstein held 81,021 shares of Caris Life Sciences worth $1.45M as of Q2 2026.
  • AllianceBernstein bought 23,945 Caris Life Sciences shares in Q2 2026, an estimated $429K.
  • Caris Life Sciences made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2208 holding.
  • AllianceBernstein first reported a position in Caris Life Sciences in Q2 2025 and has held it in 5 quarters since.
  • AllianceBernstein's Caris Life Sciences position peaked at $36.4M in Q3 2025.
  • 246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.